Company ProfilePremium

Imugene Limited

Company Profile Analysis

Ticker: IMU.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Imugene Limited - Company showcase

Year Founded & Workforce

2001

14 Employees

Imugene Limited logo

Imugene Limited Employee Contacts

9 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Imugene Limited Overview

Imugene Limited is a Sydney-headquartered, ASX-listed clinical-stage cell therapy company that, after a decade as a multi-platform immuno-oncology developer, has collapsed its pipeline onto a single asset: azercabtagene zapreleucel (azer-cel), an off-the-shelf allogeneic CD19 CAR T therapy in-licensed from Precision BioSciences in August 2023. Azer-cel is in a three-cohort Phase 1b basket study across ten US and five Australian sites, targeting CAR T-relapsed diffuse large B-cell lymphoma (DLBCL), CAR T-naïve B-cell malignancies, and patients progressing on BTK inhibitors. The asset carries three FDA Fast Track Designations (DLBCL post-CAR T; CLL/SLL; MZL). The company's investment case rests on high early response rates (82% ORR in CAR T-relapsed DLBCL; 79% in the CAR T-naïve cohort at ASCO 2026) set against acute balance-sheet fragility: A$2.6m cash at 30 June 2026, an A$105.3m FY2026 loss, a 34:1 consolidation, repeated deeply discounted raises, and an interim leadership structure after the CEO's July 2026 resignation.


Company's own description (FY2026 Annual Report). Imugene describes itself as a clinical-stage cell therapy company developing an off-the-shelf (allogeneic) CAR T therapy for blood cancers, stating that its lead and sole clinical program is azer-cel, a donor-derived CD19 CAR T that can be ready to administer within days rather than the three to six weeks required to manufacture conventional autologous CAR T from a patient's own cells. Its stated mission is to develop transformative cancer medicines to improve patients' lives, under the values of innovation, patient-centricity, relationships, integrity and excellence. The Directors' Report describes the Group as "an Australian-headquartered clinical stage cell therapy company developing an Allogeneic CAR T for blood cancers."

Independent characterisation. Imugene is best understood today as a capital-markets-funded, virtual development company holding an in-licensed late-Phase 1 cell therapy asset. It owns no manufacturing (its North Carolina cGMP facility was sold to Kincell Bio in April 2024, with Kincell now the contract manufacturer), runs a 14-person organisation, and outsources clinical execution to academic and community trial sites in the US and Australia. Value creation is entirely contingent on (i) generating registration-enabling clinical data, (ii) securing an FDA-agreed pivotal path (an FDA meeting in December 2025 reportedly validated dosing, population, endpoints and manufacturing readiness), and (iii) either licensing/partnering azer-cel with a large biopharma company or financing a pivotal study itself. The July 2026 placement included an unnamed international commercial-stage biopharmaceutical company subscribing ~14% of the placement, which management frames as a signal of strategic interest.

Business model and revenue model.

Operational footprint of the business model. The company's own accounts show the scale of de-risking via cost reduction: FY2026 payments to suppliers and employees fell A$35.7m (40%) to A$53.7m; employee benefits costs fell A$8.2m (45%); staff cash costs fell from A$20.5m to A$11.2m; executive headcount fell from 24 to 14 (FY2026 Annual Report, pp. 19–20, 32–33).

Strategy

Stated strategy themes (FY2026 Annual Report, verbatim themes).

  1. "Our lead and sole clinical program is azer-cel" — single-asset focus.

  2. Direct "capital and management attention toward the program with the strongest near-term potential to deliver for patients and shareholders."

  3. Advance azer-cel "towards later-stage development" and "a registrational pathway."

  4. Advance "discussions with major global pharmaceutical companies regarding strategic collaborations."

  5. Maintain a lean cost base — "Imugene has continued to reduce its cost base and has significantly lowered its cash outflows."

Strategic initiatives register (last 24 months).

ESG/sustainability commitments: none disclosed. Medium-term financial targets/guidance: none disclosed beyond a runway statement — the July 2026 placement was said to extend funding "into calendar year 2027" (pro forma cash A$17.8m).

Products & Services

Imugene has no marketed products. The catalogue below covers every development asset, active and discontinued.

Azer-cel (azercabtagene zapreleucel) — ACTIVE, LEAD AND SOLE CLINICAL PROGRAM

AttributeDetail
DescriptionOff-the-shelf, allogeneic, donor-derived CAR T cell therapy targeting CD19
OriginExclusive worldwide oncology licence from Precision BioSciences (Aug 2023); developed with Precision's ARCUS gene-editing platform†
MechanismHealthy-donor T cells engineered to express a CD19 CAR; expanded in large numbers for multiple patients; available "within days" vs. 3–6 weeks for autologous CAR T
RegimenLymphodepletion + azer-cel, with interleukin-2 (IL-2) in DLBCL cohort; concurrent BTKi in Cohort 3
Target indicationsDLBCL (incl. Richter's transformation), FL, CLL/SLL, MZL, WM, MCL, PCNSL
TrialPhase 1b open-label multi-centre basket study; 10 US + 5 Australian sites
Patients dosed (cumulative, incl. Precision-era)>130 patients dosed with azer-cel to date (FY2026 Annual Report)
Regulatory designationsFDA Fast Track: R/R DLBCL post-CAR T; R/R CLL/SLL and R/R MZL (June 2026)
ManufacturingKincell Bio (Research Triangle Park, NC) under manufacturing supply agreement; process/analytical development transferred to Kincell
Target customerHaematologists at cell therapy-accredited centres; also potentially community settings given off-the-shelf logistics
Latest version / launch yearInvestigational; no approval. Pivotal study pathway discussed with FDA (Dec 2025)
PricingNot applicable / not disclosed
CohortPopulationLatest disclosed dataDate/Source
1 — CAR T-relapsed DLBCLDLBCL relapsed/refractory after autologous CAR T; ≥3 prior linesORR 82% (14/17): 7 CR, 7 PR1 Dec 2025; ASH 2025 oral
2 — CAR T-naïveSeven B-cell malignancies, 1–3 prior lines, no prior CAR TASCO 2026: ORR 79% (n=24 evaluable; 25 treated); 93% in 14 indolent patients; 0 Grade ≥3 CRS. By indication: DLBCL/RT 67% (n=6), MZL 83% (n=6), CLL 100% (n=4), PCNSL 50% (n=4), FL 100% (n=3), WM 100% (n=1)29 May 2026 (Dr Supriya Gupta, Univ. of Minnesota)
3 — Concurrent BTKiProgressed on BTKiFirst patient dosed 28 May 2026; first CR (FL) 30 Jun 2026; CR in first MCL patient (1 Jul 2026); PR in second FL patient (27 Jul 2026); 5 patients dosed at report dateFY2026 Annual Report
AggregateAll three cohorts44 evaluable: 19 CR + 17 PR (Aug 2026); 75% ORR across 55 patients (7 Oct 2026 announcement summary)Chairman's letter; StockWire X

Cohort-level data register.

CF33-hNIS (VAXINIA) — DISCONTINUED (FY2026)

Oncolytic chimeric orthopoxvirus (CF33) armed with the human sodium iodide symporter (hNIS) for imaging/radiotherapy combination, licensed from City of Hope†. Evaluated in the Phase 1 MAST trial in solid tumours, including bile tract cancer, with FDA Orphan Drug Designation recorded in the company's development table. Development ceased and assets impaired in FY2026.

CF33-CD19 (onCARlytics) — DISCONTINUED (FY2026)

Oncolytic virus engineered to express CD19 on solid-tumour cells, rendering them targetable by CD19 CAR T therapies (concept: "mark" solid tumours for blood-cancer CAR Ts). Phase 1 and IND achieved per company development table. Repositioned in H1 FY2026 via a collaboration with China-based JW Therapeutics; the proposed joint development was subsequently ceased.

HER-Vaxx (IMU-131) — INACTIVE

B-cell peptide vaccine inducing polyclonal anti-HER2 antibodies, studied in Phase 2 in HER2+ gastric cancer (HERIZON†) and the neoadjuvant IMPRINTER study (first patient June 2023, FY2023 Annual Report). Intangible's useful life reassessed in FY2026, leading to A$4.5m accelerated amortisation.

PD1-Vaxx — DISCONTINUED (FY2026)

B-cell peptide vaccine targeting PD-1 (Phase 1/2 in lung and colorectal settings†). Licence returned to Ohio State University.

Services

None. Imugene provides no commercial services.

Financial Narrative

Sources: FY2026 Annual Report (FY2026 audited; FY2025 restated; 1 July 2024 restated opening balance sheet; 5-year KPI table); FY2023 Annual Report (FY2022–FY2023 cash and net assets); StockAnalysis, Kalkine and InvestSMART (Morningstar) for FY2022–FY2024 income-statement and cash-flow line items as originally reported.

Income Statement

Notes and reconciliation:

  • FY2025 R&D shown at A$46.69m as originally reported (aggregator); restated FY2025 R&D is A$24.93m and restated operating loss A$49.18m (FY2026 Annual Report). FY2025 originally reported net loss was approx. A$69.0m (InvestSMART/Morningstar) vs. restated A$47.26m.

  • Statutory net loss after tax: FY2022 A$37.87m; FY2023 A$37.91m (Annual Report; Preliminary Final Report showed A$39.17m — discrepancy between preliminary and audited); FY2024 approx. A$149.7m (InvestSMART "after abnormals", originally reported) vs. A$157.6m total comprehensive loss in the company's own 5-year table; FY2025 A$47.26m (restated); FY2026 A$105.34m.

  • Gross profit, EBITDA and margins are not meaningful: no revenue. EBITDA is not reported; FY2026 operating loss includes A$20.2m impairment and A$4.5m accelerated amortisation, so EBITDA-equivalent loss is approx. A$81m before other depreciation (indicative only).

  • Revenue CAGR: not meaningful.

Commentary. The FY2022–FY2023 period reflects a multi-asset immuno-oncology company spending ~A$50m p.a. in operating expenses, partly offset by R&D Tax Incentive income. FY2024 is the inflection: the azer-cel acquisition, the build-out and subsequent sale of a US manufacturing facility (with an A$11.3m loss on asset disposal per StockAnalysis), and a three-program clinical slate drove the loss to its peak. FY2025 shows the first restructuring benefits, and the restatement — which removed a provision for future milestone-based expenses and recognised a A$28.2m non-cash gain in FY2025 — materially flatters the FY2025 comparative. FY2026's A$105.3m loss is dominated by non-cash and one-off items: A$20.2m impairments, the US$8m Precision milestone (expensed under the new policy), A$4.5m HER-Vaxx amortisation and a A$12.73m fair-value loss on the convertible notes within G&A. Management states that underlying R&D fell 3% and underlying G&A fell 42% year-on-year once these items are removed (FY2026 Annual Report, pp. 19–20).

Balance Sheet

FY2024 balance-sheet figures use the restated 1 July 2024 opening position; FY2023 net assets per audited Annual Report (Preliminary Final Report showed A$188.37m).

Convertible notes: face value reduced from A$20.0m (start of FY2026) to A$11.783m at 30 June 2026 via redemptions and refinancing; senior, unsecured, zero-coupon; maturity January 2030 (FY2026 Annual Report). Carrying value (A$6.18m) differs from face value; valuation basis per Note 12. Net tangible assets per security: 1.0 cent (30 June 2026) vs 11.1 cents (30 June 2025).

Commentary. The balance sheet has been almost entirely consumed. Cash fell 98% from the FY2023 peak; intangibles collapsed after the FY2026 impairments; working capital turned negative (–A$4.2m) at 30 June 2026 for the first time in the period reviewed, a condition relieved only by the July 2026 A$11.1m placement (pro forma cash A$17.8m per the placement announcement). Accumulated losses now exceed A$440m against A$427m of contributed capital.

Cash Flow

FY2022–FY2024 from Kalkine/StockAnalysis (Morningstar); FY2025–FY2026 audited. FY2026 free cash flow excludes the A$4.59m Azer-cel milestone (classified as investing).

Quarterly cash trajectory (Appendix 4C).

Discrepancy: Q4 FY2026 Appendix 4C reports A$2.510m cash at 30 June 2026 vs. A$2.630m in the audited accounts.

Ratios

Not meaningful for a pre-revenue company: ROIC, net debt/EBITDA, interest coverage, asset turnover, cash conversion cycle. Calculations are analyst-derived from figures above.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment

MetricFY2024FY2025FY2026

Other income (AUD Mn)

4.974.452.09

Operating loss (AUD Mn)

-141.82-49.18-105.70

Loss before tax (AUD Mn)

-149.70-47.26-105.34

Capital Programmes

ProgrammeModalityStatus (Oct 2026)Accounting treatment

Azer-cel

Allogeneic CD19 CAR T

Active — Phase 1b, 3 cohorts

Licence intangible; milestone expensed under new policy

CF33-hNIS (VAXINIA)

Oncolytic virus

Discontinued FY2026

Impaired (part of A$20.2m)

CF33-CD19 (onCARlytics)

Oncolytic virus + CD19 CAR T

Discontinued (incl. JW Therapeutics collaboration)

Impaired (part of A$20.2m)

HER-Vaxx

B-cell HER2 peptide vaccine

Inactive

Accelerated amortisation A$4.5m

PD1-Vaxx

B-cell PD-1 peptide vaccine

Discontinued; licence returned to Ohio State University

—

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from ordinary activities (AUD Mn)

00000

Other income (AUD Mn)

12.9711.784.974.452.09

R&D expense as reported (AUD Mn)

36.6130.8686.8946.6975.57

G&A expense (AUD Mn)

14.0620.4359.9127.8231.86

Operating loss (AUD Mn)

-37.70-39.52-141.82-49.18-105.70

Total comprehensive loss attributable to owners (AUD Mn)

-37.85-38.13-157.63-48.02-105.96

Basic loss per share, post-consolidation (A$ cents)

22.7820.6675.6021.9632.49

Dividends per share (AUD)

00000

Key Financials (AUD)

Line itemFY2026FY2025 (restated)Change

Other income

2,086,1034,445,407-53%

Other gains/(losses)

(365,530)(876,341)

n/m

Research and development expenses

(75,566,877)(24,931,608)+203%

General and administrative expenses

(31,857,196)(27,817,558)+15%

Operating loss

(105,703,500)(49,180,100)+115%

Finance income

492,1532,081,324-76%

Finance expenses

(125,477)(163,075)-23%

Loss before income tax

(105,336,824)(47,261,851)+123%

FX translation (OCI)

(623,157)(760,384)

n/m

Total comprehensive loss

(105,959,981)(48,022,235)+121%

Basic and diluted LPS (AUD)

(0.32)(0.22)

n/m

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Cash and cash equivalents (AUD Mn)

99.89153.1593.1121.942.63

Intangible assets (AUD Mn)

32.6930.4934.1231.694.86

Net assets / total equity (AUD Mn)

138.70189.63109.8558.099.01

Balance Sheet (1 Jul 2024 (restated)–30 Jun 2026)

Balance sheet detail (AUD Mn)1 Jul 2024 (restated)30 Jun 2025 (restated)30 Jun 2026

Total current assets

113.0341.749.82

Total non-current assets

38.3641.8413.21

Total assets

151.4083.5923.03

Trade and other payables

7.8111.726.26

Provisions (current)

27.780.500.00

Convertible note (current, carrying value)

0.009.256.18

Lease liabilities (current + non-current)

1.281.400.11

Total liabilities

41.5425.5014.02

Working capital (current assets less current liabilities)

73.0317.01-4.20

Total debt (convertible notes + leases)

1.2810.656.30

Short-term debt

0.6510.396.30

Long-term debt

0.630.260.00

Net debt / (net cash)

-91.83-11.293.67

Goodwill

0.000.000.00

Issued capital

370.31380.68427.27

Accumulated losses

-298.22-339.37-440.87

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

-30.85-31.47-101.73-75.57-44.74

Free cash flow (AUD Mn)

-31.11-31.47-108.80-83.12-44.74

Financing cash flow (AUD Mn)

101.3482.9849.4317.3729.87

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

FY2026 vs FY2025 cash flow detail (AUD Mn)

FY2026 vs FY2025 cash flow detail (AUD Mn)FY2025FY2026

Payments to suppliers and employees

-89.45-53.75

R&D Tax Incentive received

11.118.51

Interest received

2.370.49

Capex (PP&E)

-7.550.00

Payments for azer-cel assets / milestones

-6.91-4.59

Proceeds from share issues

0.0040.94

Convertible note issued / (redeemed)

20.00-7.38

Share issue costs

-1.32-2.67

Cash Flow (Quarterly)

MetricQ2 FY2026Q3 FY2026Q4 FY2026

Quarter-end cash (AUD Mn)

14.105.962.51

Net operating cash used (AUD Mn)

—9.679.21

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025FY2026

ROE (total comprehensive loss / avg equity, %)

-23-105-57-316

ROA (net loss / avg total assets, %)

not computable

not computable

-40-198

Current ratio (x)

—2.831.690.70

Debt / equity (x)

—0.010.180.70

Geography Overview

GeographyActivityFY2026 indicator

United States

Clinical sites, CMO function, manufacturing (Kincell, NC), FDA engagement

10 of 15 trial sites

Australia

HQ (Sydney), Board, CFO, R&D Tax Incentive claims, trial sites

5 of 15 trial sites; A$2.7m FY2025 R&D refund

China

JW Therapeutics onCARlytics collaboration

Ceased FY2026

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025FY2026

Share price at year end (AUD)

6.123.062.040.4420.115

Share price high (AUD)

21.4210.885.102.720.46

Share price low (AUD)

4.422.721.360.340.09

Market capitalisation 30 June (AUD Mn)

1,0565844099748

Valuation Multiples

MultipleImugeneComment

P/E

n/m

Loss-making

EV/EBITDA

n/m

Negative EBITDA

EV/Sales

n/m

Nil revenue

P/B

~2x (indicative)

~A$40m market cap vs ~A$20m pro forma equity (A$9.0m + A$11.1m raise)

EV (indicative)

~A$35–40m

Market cap + A$11.8m note face value – ~A$13–18m pro forma cash (estimate)

Share Price & Returns

DateInstrumentAmount (AUD Mn)Price (AUD)Attaching securities

Jul 2025

Placement + SPP

24.920.33

3 options per 4 shares, ex. A$0.43, piggyback ex. A$0.86 (exp. 30 Jun 2028)

Mar 2026

Placement + SPP

16.000.18

1:1 options ex. A$0.18, piggyback ex. A$0.30 (exp. 30 Jun 2029)

Jul 2026

Two-tranche placement

11.120.095

None disclosed

Capital Instruments

InstrumentFace value (AUD Mn)CouponMaturityHolder

Senior unsecured zero-coupon convertible notes

11.783 (30 Jun 2026)

0%

January 2030

CVI Investments, Inc.

New convertible notes (Aug 2026 roll)

2.1 (replacing existing notes)

0%—

CVI Investments, Inc.

Warrants (Aug 2026)

Up to 1.68 if exercised

——

CVI Investments, Inc.

“—” = not publicly disclosed.

Analyst Conclusions

Management guidance. No financial guidance. Management states that azer-cel is not expected to generate revenue in the short term; that July 2026 funding extends runway into calendar 2027; and that proceeds support Phase 1b expansion, regulatory engagement, manufacturing scale-up and partnering discussions. The FY2026 Directors' Report states that, pending successful development, azer-cel "could increase shareholder value by many multiples."

Consensus growth expectations. None available (pre-revenue; no reliable consensus).

Bull case.

  1. Clinical signal is consistent across cohorts: 82% ORR post-CAR T DLBCL, 79% ORR CAR T-naïve, and early CRs in BTKi-refractory FL and MCL — supporting a broad label strategy.

  2. Regulatory scaffolding is in place: three Fast Track Designations and an FDA meeting validating pivotal design elements shorten the path to a registrational study and potential Accelerated Approval.

  3. Valuation asymmetry: at ~A$40m market cap, any partnering deal with a global biopharma (one already participated in the July placement) could re-rate the stock materially relative to the remaining Precision milestones.

Bear case.

  1. Funding is existential: A$2.6m cash at year end, ~A$9m quarterly operating burn in H2 FY2026, and a pivotal trial unfunded — further heavy dilution is highly probable.

  2. Data are small, single-arm and immature: many subgroup response rates rest on 1–6 patients; durability versus approved autologous CAR T and bispecifics is unproven.

  3. Execution and governance risk: no CEO, a new CMO, a second-strike remuneration history, and serial program write-downs (A$20.2m impairment) that question prior capital allocation.

Key catalysts and monitorables (next 12 months).

Concluding analyst verdict.

Imugene in October 2026 is a fundamentally different company from the A$1bn multi-platform immuno-oncology story of 2022. Through write-offs, divestment and restructuring, it has become a 14-person, single-asset allogeneic CAR T developer whose entire enterprise value hangs on azer-cel. The clinical data are genuinely encouraging for an off-the-shelf CD19 product: an 82% response rate in DLBCL patients who have already failed autologous CAR T, a 79% response rate in CAR T-naïve B-cell malignancies with no high-grade cytokine release syndrome at ASCO, and complete responses in the first evaluable BTKi-refractory patients. Three Fast Track Designations and a constructive FDA meeting give the program a credible regulatory scaffold, and the hiring of a CMO with direct allogeneic pivotal experience is a sensible fit.

The balance sheet, however, overwhelms the science in the near term. The company ended FY2026 with A$2.6m cash and negative working capital, relying on a A$11.1m placement at a ~30% discount to reach calendar 2027. Raise prices fell from A$0.33 to A$0.095 within twelve months, a convertible note overhang remains to 2030, and Precision is owed milestones and royalties on any success. Leadership is interim, and shareholders delivered a second strike on pay in 2025.

Our assessment is that Imugene is a high-risk, binary option on a partnering or licensing transaction. The early data are strong enough to attract strategic interest — as the biopharma participation in the July raise suggests — but small samples and short follow-up leave durability unproven against well-funded allogeneic rivals and approved bispecifics. Absent a partner, a self-funded pivotal trial implies dilution on a scale that could largely transfer any clinical upside to new capital providers. Investors should treat the next two to three quarters — CEO appointment, ASH 2026 updates and any partnering news — as decisive, and size exposure accordingly.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / backgroundFY2026 total remuneration (A$, incl. share-based)

Paul Hopper

Executive Chairman (overseeing leadership pending CEO appointment)

Director since 31 Oct 2012

20+ years managing and funding biotech/healthcare companies in Australia and the US; director of Radiopharm Theranostics (ASX: RAD); former director Chimeric Therapeutics (until 25 Nov 2025)

463,366

Darren Keamy

Chief Financial Officer and Company Secretary

Since 4 Mar 2025

CFO and Company Secretary, Clinuvel Pharmaceuticals (2005–2024)

623,216

Dr John Le Gall, MD MBA

Chief Medical Officer

Since 7 Oct 2026

Allogene Therapeutics — redesigned pivotal development plan for cema-cel (allogeneic CD19 CAR T)

—

CEO

Vacant

Since 24 Jul 2026

Search commenced July 2026

—

“—” = not publicly disclosed.

Executive Leadership Team (FY2026 remuneration (AUD))

NameRoleDepartureContextFY2026 remuneration (AUD)

Leslie Chong

CEO & Managing Director

24 Jul 2026 (announced 27 Jul)

Personal reasons; ~11 years' service; six months' salary cessation payment; 170,404 unvested performance rights accelerated

1,616,117

Dr John Byon

Chief Medical Officer

Oct 2026

Mutual agreement; remains consultant; role restructured for single-asset company

1,899,603

Dr Bradley Glover

Chief Operating Officer

2 Jan 2026

To focus on other business interests

-40,649 (reflects share-based payment reversal)

Dr Paul Woodard

Former executive (FY2025 KMP)

FY2025

—

741,102 (FY2025)

Mike Tonroe

Former CFO

FY2025

Replaced by Darren Keamy

244,116 (FY2025)

Dr Monil Shah

Former executive (FY2025 KMP)

FY2025

—

740,211 (FY2025)

“—” = not publicly disclosed.

Directors' Remuneration

NameSalary & feesCash bonusLeaveSuper / 401kTotal cash

Paul Hopper

260,10075,249——335,349

Leslie Chong

787,950163,5007,63830,000989,088

Darren Keamy

355,250151,34412,51330,000549,107

Dr John Byon

695,580286,38154,20643,8261,079,993

Dr Bradley Glover

382,665—-89,293—293,372

Kim Drapkin (NED)

88,856———88,856

Dr Jakob Dupont (NED)

81,478———81,478

Dr Lesley Russell (NED)

74,042———74,042

Total KMP

2,725,921676,474-14,936103,8263,491,285

Board of Directors

NameRoleAppointedIndependenceCommitteesBackgroundOther boards

Paul Hopper

Executive Chairman

31 Oct 2012

Not independent (executive)

—

Biotech capital markets, chair/CEO roles AU & US

Radiopharm Theranostics

Dr Lesley Russell

NED

23 Apr 2019

Independent

Rem & Nom (member); Audit & Risk (member)

Haematologist/oncologist; former CMO with multiple FDA/EMA approvals

Chimeric Therapeutics; Enanta Pharmaceuticals

Dr Jakob Dupont

NED

7 Sep 2022

Independent

Rem & Nom (Chair); Audit & Risk (member)

Oncology drug developer; Executive Venture Partner, Sofinnova Investments

Pyxis Oncology; Bolt Biotherapeutics

Kim Drapkin

NED

21 Jun 2023

Independent

Audit & Risk (Chair); Rem & Nom (member)

25+ years biotech finance leadership

Acumen Pharmaceuticals; LENZ Therapeutics

Dr Charmaine Gittleson

NED

30 Jun 2026

Independent

None yet

Former CMO, CSL Limited; 20+ years drug development and regulatory

Chair, Percheron Therapeutics; PolyNovo; George Medicines

Michael Kotsanis

NED

30 Jun 2026

Independent

None yet

35 years pharma operations; former CEO Acrux

ICE Pharma (private)

Major Shareholders

HolderShares (post-consolidation)Basis

Paul Hopper

12,266,512

KMP holdings, 30 Jun 2026

Leslie Chong (former CEO)

3,483,806

At 30 Jun 2026

Dr Lesley Russell

624,651

30 Jun 2026

Dr Bradley Glover (former)

245,233

At cessation

Dr John Byon (former)

244,600

30 Jun 2026

Kim Drapkin

32,914

30 Jun 2026

Dr Jakob Dupont

32,038

30 Jun 2026

Total KMP

16,929,754

~4% of ~425m shares (indicative)

Competitive Landscape

Key Competitors

CompetitorSegmentProduct(s)Relative positioning vs azer-celRevenue / scale

Gilead / Kite

Autologous CD19 CAR T

Yescarta, Tecartus

Approved standard; manufacturing lag 2–4+ weeks

—

Bristol Myers Squibb

Autologous CD19 CAR T

Breyanzi

Approved across DLBCL, FL, CLL, MCL, MZL

—

Novartis

Autologous CD19 CAR T

Kymriah

Approved; mature

—

Allogene Therapeutics

Allogeneic CD19 CAR T

Cema-cel (ALLO-501A)

Most direct allogeneic comparator; pivotal-stage consolidation strategy

Pre-revenue

CRISPR Therapeutics

Allogeneic CD19 CAR T

CTX112

Gene-edited allogeneic competitor

Pre-product revenue in oncology

Caribou Biosciences

Allogeneic CD19 CAR T

CB-010

Allogeneic competitor in LBCL

Pre-revenue

Roche (incl. Poseida)

Allogeneic CAR T; bispecifics

P-CD19CD20-ALLO1; Columvi, Lunsumio

Big-pharma resources across modalities

Large-cap

AbbVie / Genmab

Bispecific

Epkinly (epcoritamab)

Off-the-shelf alternative already approved

Large-cap

Autolus

Autologous CD19 CAR T

Obe-cel (Aucatzyl)

Differentiated autologous

Early commercial

Arovella Therapeutics (ASX: ARL)

Allogeneic CAR-iNKT

ALA-101 (CD19)

ASX peer, earlier stage

Pre-revenue

Chimeric Therapeutics (ASX: CHM)

CAR T / NK

CHM CDH17, CORE-NK

ASX cell therapy peer

Pre-revenue

BTKi incumbents (AbbVie/J&J, AstraZeneca, BeiGene)

Small molecules

Imbruvica, Calquence, Brukinsa

Partner/combination opportunity rather than pure competitor

Large-cap

Competitor Detail

MetricImugene (FY2026)

Revenue

A$0

Lead allogeneic CD19 stage

Phase 1b (3 FTDs)

Cash at latest period

A$2.6m (Jun 2026); ~A$17.8m pro forma

R&D intensity

70% of opex

Recent Developments

--

Company Snapshot

14

Employees

2001

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • 82% ORR (14/17; 7 CR) in CAR T-relapsed DLBCL — a population with few options (1 Dec 2025).
  • ASCO 2026 oral: 79% ORR in CAR T-naïve cohort; 93% in indolent disease; no Grade ≥3 CRS.
  • Three FDA Fast Track Designations (DLBCL; CLL/SLL and MZL granted June 2026).
  • FDA meeting (Dec 2025) validated dosing, population, endpoints and manufacturing readiness.
  • Lean structure: 14 staff; payments to suppliers/employees down 40% to A$53.7m (FY2026).
  • Early BTKi-combination signal: first two evaluable patients achieved CRs (FL, MCL), July 2026.

Weaknesses

  • Cash of A$2.6m at 30 June 2026; negative working capital of A$4.2m.
  • FY2026 net loss A$105.3m; accumulated losses A$440.9m.
  • Single-asset concentration after discontinuing CF33, onCARlytics and PD1-Vaxx.
  • CEO position vacant since 24 July 2026; CMO and COO replaced within 10 months.
  • Second strike on Remuneration Report (30.55% against, Nov 2025).
  • Share price down ~98% from 30 June 2022 (A$6.12 → A$0.115, post-consolidation).

Opportunities

  • Partnering: international commercial-stage biopharma took ~14% of the July 2026 placement.
  • BTKi market ~US$12bn (2025) with azer-cel positioned for concurrent use.
  • Accelerated Approval/Priority Review eligibility via Fast Track.
  • Indications without approved CAR T (PCNSL, WM).
  • New CMO with allogeneic pivotal design experience (Allogene cema-cel).
  • Continued R&D Tax Incentive refunds (A$8.5m received FY2026).

Threats

  • Further dilution: placements at A$0.33 → A$0.18 → A$0.095 within 12 months.
  • Precision milestone obligations (up to ~US$198m†) and royalties reduce economics.
  • Allogeneic competitors (Allogene, CRISPR, Caribou) with larger balance sheets.
  • Approved bispecifics (Epkinly, Columvi) as off-the-shelf alternatives.
  • Convertible note overhang (A$11.783m face; Jan 2030 maturity) and warrants.
  • Small sample sizes: subgroup ORRs based on n=1–6 patients may not replicate.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Jul 202534:1 share consolidationResets share count; signal of prior dilution
14 Jul 2025Azer-cel DLBCL best ORR 75%, CR 55%Data momentum ahead of raise
16 Jul 2025A$22.5m placement + SPP (A$2.42m) at A$0.33 with 3:4 optionsFunding into FY2026
Sep 202513/16 ORR (81%) in DLBCL cohortData maturation
13 Nov 2025AGM second strike; spill defeatedShareholder dissatisfaction on pay
1 Dec 202582% ORR (14/17; 7 CR/7 PR) in CAR T-relapsed DLBCLStrongest cohort 1 dataset
Dec 2025ASH 2025 oral presentation (Orlando)Scientific validation
Dec 2025Positive FDA meeting on pivotal elementsRegulatory de-risking
Dec 2025First Precision milestone triggered (US$8m)Cash/expense impact
2 Jan 2026COO Bradley Glover resignsExecutive attrition
30 Jan 2026Q2 4C: A$14.1m cashRunway pressure visible
25 Feb 2026H1 FY2026 loss A$37.8m (down 22%)Cost-out evidence
25 Feb 2026A$2.7m R&D tax refund (FY2025)Non-dilutive funding
10–11 Mar 2026CAR T-naïve data: CLL/SLL 100% ORR; MZL 5/6; protocol amended for BTKi + MCL; A$12m placement + SPP (A$16m) at A$0.18Funding + new cohort
Mar 2026Ten News First national coverage of azer-cel patientPublic profile
1 Apr 2026Azer-cel selected for ASCO 2026 oralVisibility
23 Apr 2026EGMApprovals for capital initiatives
30 Apr 2026Q3 4C: A$5.96m cash; A$9.67m operating outflowRunway < 1 quarter at period end
22 May 2026ASCO abstract: 81% ORR CAR T-naïveData
26 May 2026Board enhancement announced (Gittleson, Kotsanis)Governance
28–29 May 2026First BTKi-cohort dosing; ASCO oral: 79% ORR (n=24), 93% indolent, no Grade ≥3 CRSKey data event
9 Jun 2026FDA Fast Track: CLL/SLL and MZLRegulatory
30 Jun 2026First CR in BTKi cohort (FL)Cohort 3 signal
1 Jul 2026CR in first MCL patient (BTKi cohort)Cohort 3 signal
3 Jul 2026Trading halt for capital raising—
7 Jul 2026A$11.12m placement at A$0.095 (29.6% discount); strategic biopharma investor ~14%Survival funding; strategic signal
24/27 Jul 2026CEO Leslie Chong resignsLeadership gap
27 Jul 2026Third BTKi-cohort response (PR, FL)Data
31 Jul 2026Q4 4C: A$2.51m cashPre-raise cash low
19 Aug 2026Shareholders approve Tranche 2 (43.4m shares, A$4.1m directors' placement)Funding completion
21 Aug 2026CVI note amendment; 25.3m warrantsDebt restructuring
28 Aug 2026FY2026 results: A$105.3m loss; A$2.6m cashAnnual reporting
7 Oct 2026Dr John Le Gall appointed CMO; Dr Byon steps down; 75% ORR across 55 patients citedLeadership/clinical continuity

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Results by Segment: Other income fell from AUD 5 Mn in FY2024 to AUD 2.1 Mn in FY2026.
Imugene Limited — Results by Segment
Series (AUD Mn)FY2024FY2025FY2026
Other income54.52.1
Operating loss-141.8-49.2-105.7
Loss before tax-149.7-47.3-105.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.